omniture
logo
Search
DOERBIO杭州道尔生物科技有限公司
Media Room

Latest News

rss

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia

HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a c...

2024-09-30 15:00 1064

Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia

HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a cli...

2024-07-05 15:56 3470

Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA

HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a cli...

2023-08-01 17:08 1148

Doer Biologics Announces License Agreement with BioNTech

HANGZHOU, China, July 10, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a cl...

2023-07-11 11:49 1936

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

HANGZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, [ December 9th, 2022], Zhe...

2022-12-16 09:00 1785